On August 16, 2018, Saxena White secured a major victory with an important decision issued by the New Jersey District Court in In Re Novo Nordisk Securities Litigation C.A. No. 3:17-cv-00209. In a 20-page opinion, Honorable Brian R. Martinotti denied Defendants’ motion to dismiss in its entirety.

The Court found that Saxena White properly alleged that Novo Nordisk and its senior executives knowingly and falsely attributed the Company’s growth to the efficacy of its products rather than undisclosed rebates to ensure that its drugs were placed on preferred formularies. The Court further noted that not only were multiple former employees able to corroborate the Defendants’ knowledge of Novo Nordisk’s sales practices, but that the Defendants were also financially incentivized to engage in this fraudulent behavior.

The case is now in the discovery phase.